EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieVergleichsstudieOpen Access · CC BY-NC 4.0

Combined therapy with dutasteride and tadalafil vs dutasteride or tadalafil monotherapy in benign prostatic hyperplasia: a randomised phase III trial

Seung Wook Lee iD, Seung Hwan Lee, Jae Heon Kim iD, Joon Hwa Noh, Jun Ho Lee, U-Syn Ha iD, Cheol Young Oh, Taek Won Kang, Kyung Seop Lee, Sangchul Lee, Deok Hyun Han, Jun Hyun Han iD und 9 weitere

BJU International · 2026

DOI: 10.1111/bju.70163 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift BJU International, 2026. Verfasst von Seung Wook Lee und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, South Korea. Hauptthemen laut MEDLINE: 5-alpha Reductase Inhibitors, Dutasteride, Phosphodiesterase 5 Inhibitors, Prostatic Hyperplasia. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Dongkook Pharmaceutical Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate the efficacy and safety of a fixed‐dose combination (FDC) of dutasteride and tadalafil vs monotherapy in patients with benign prostatic hyperplasia (BPH). Patients and Methods This phase III trial enrolled 667 patients. After screening and washout, eligible patients were stratified by the baseline International Prostate Symptom Score (IPSS) and randomised (1:1:1) to receive FDC dutasteride 0.5 mg/tadalafil 5 mg (FDC 0.5/5 mg), dutasteride 0.5 mg, or tadalafil 5 mg for 48 weeks. The primary endpoint was the change in total IPSS from baseline to Week 48. Efficacy and safety were assessed at 4, 12, 24, 36, and 48 weeks.

Results

In total, 619 patients were analysed for efficacy. The least squares (LS) mean (standard error [ se] ) change in total IPSS at 48 weeks from baseline was −9.49 (0.37) for the FDC 0.5/5 mg group vs –4.40 (0.37) for dutasteride 0.5 mg group (LS mean difference [LSMD] –5.09, 95% confidence interval [CI] −6.13 to −4.50; P < 0.001), and −9.53 (0.36) for the FDC 0.5/5 mg group vs –4.24 (0.37) for tadalafil 5 mg group (LSMD –5.29, 95% CI −6.30 to −4.27; P < 0.001). The FDC 0.5/5 mg group demonstrated the most pronounced improvement in quality of life. Although the maximum urinary flow rate and post‐void residual volume improved in all groups, differences were not statistically significant. In the comparison between the FDC 0.5/5 mg and dutasteride 0.5 mg groups, the LSMD (95% CI) of change from baseline to Week 48 in the international index of erectile function ‐ erectile function (IIEF ‐ EF) total score was 4.03 (2.35 to –5.71) ( P < 0.05). Among the 655 patients analysed for safety, treatment‐emergent adverse events occurred in 32.88% (FDC 0.5/5 mg) vs 21.20% (dutasteride 0.5 mg) and 26.48% (tadalafil 5 mg), with few serious adverse events observed.

Conclusions

The FDC 0.5/5 mg demonstrated superior efficacy, and an acceptable safety profile compared with dutasteride and tadalafil monotherapies in patients with BPH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

5-alpha Reductase InhibitorsDutasteridePhosphodiesterase 5 InhibitorsProstatic HyperplasiaTadalafilAgedHumansMaleMiddle AgedAzasteroidsCarbolinesDouble-Blind MethodDrug Therapy, CombinationTreatment Outcome

Stichwörter der Autor:innen

LUTSbenign prostatic hyperplasiadutasteridefixed‐dose combinationtadalafil

Substanzen

5-alpha Reductase InhibitorsAzasteroidsCarbolinesDutasteridePhosphodiesterase 5 InhibitorsTadalafil

Autor:innen und Institutionen

  • Department of Urology, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, South Korea.
  • Department of Urology, Yonsei University College of Medicine, Seoul, South Korea.
  • Department of Urology, Soonchunhyang University College of Medicine, Seoul, South Korea.
  • Department of Urology, Kwangju Christian Hospital, Gwangju, South Korea.
  • Department of Urology, Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, South Korea.
  • Department of Urology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.

ORCID-Profile: Seung Wook Lee, Jae Heon Kim, U-Syn Ha, Jun Hyun Han, Byung Ha Chung, In Gab Jeong

Förderung

  • Dongkook Pharmaceutical Co., Ltd.

Zitieren

APA

Lee, S. W., Lee, S. H., Kim, J. H., Noh, J. H., Lee, J. H., Ha, U. S., Oh, C. Y., Kang, T. W., Lee, K. S., Lee, S., Han, D. H., Han, J. H., Song, S. H., Park, H. J., Chung, B. H., Min, G. E., Jeong, I. G., Moon, K. H., Kim, W. T., …, & Kim, C. S. (2026). Combined therapy with dutasteride and tadalafil vs dutasteride or tadalafil monotherapy in benign prostatic hyperplasia: a randomised phase III trial. BJU International. https://doi.org/10.1111/bju.70163

Vancouver

Lee SW, Lee SH, Kim JH, Noh JH, Lee JH, Ha US, et al. Combined therapy with dutasteride and tadalafil vs dutasteride or tadalafil monotherapy in benign prostatic hyperplasia: a randomised phase III trial. BJU International. 2026. doi:10.1111/bju.70163

BibTeX
@article{Lee2026,
  author = {Lee, Seung Wook and Lee, Seung Hwan and Kim, Jae Heon and Noh, Joon Hwa and Lee, Jun Ho and Ha, U-Syn and Oh, Cheol Young and Kang, Taek Won and Lee, Kyung Seop and Lee, Sangchul and Han, Deok Hyun and Han, Jun Hyun and Song, Sang Hoon and Park, Hyun Jun and Chung, Byung Ha and Min, Gyeong Eun and Jeong, In Gab and Moon, Kyung Hyun and Kim, Won Tae and Lee, Ji Youl and Kim, Choung-Soo},
  title = {Combined therapy with dutasteride and tadalafil vs dutasteride or tadalafil monotherapy in benign prostatic hyperplasia: a randomised phase III trial},
  journal = {BJU International},
  year = {2026},
  doi = {10.1111/bju.70163}
}
Kostenlos starten →